Pharma & Biotech
You will receive alerts when there are new announcements on Paradigm Biopharmaceuticals Ltd
Only registered members can use this feature.
Paradigm Biopharmaceuticals Ltd (ASX:PAR) is a late-stage drug development company with the mission to develop and commercialise pentosan polysulphate sodium for the treatment of pain associated with musculoskeletal disorders.
Paradigm will be focused on Phase 3 trials of its drug Zilosul® during 2021, COO Jeannie Joughin told Proactive.
© Proactive 2021.
Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority. Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.